Noile-Immune Biotech (TSE:4893) COGS-to-Revenue : 0.00 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Noile-Immune Biotech COGS-to-Revenue?

Noile-Immune Biotech's Cost of Goods Sold for the three months ended in Jun. 2024 was 円0.0 Mil. Its Revenue for the three months ended in Jun. 2024 was 円0.0 Mil.

Noile-Immune Biotech's COGS to Revenue for the three months ended in Jun. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Noile-Immune Biotech's Gross Margin % for the three months ended in Jun. 2024 was N/A%.

Noile-Immune Biotech COGS-to-Revenue Historical Data

The historical data trend for Noile-Immune Biotech's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noile-Immune Biotech COGS-to-Revenue Chart

Noile-Immune Biotech Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

0.03

0.23

0.01

Noile-Immune Biotech Quarterly Data
	Dec20	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
COGS-to-Revenue	Get a 7-Day Free Trial					0.24	-	0.06	0.08	-

Noile-Immune Biotech COGS-to-Revenue Calculation

Noile-Immune Biotech's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.257	/	316.818
	=	0.01

Noile-Immune Biotech's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Noile-Immune Biotech (TSE:4893) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Noile-Immune Biotech's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Noile-Immune Biotech COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Noile-Immune Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

2-12-10 Shiba-Daimon, Minato-ku, Tokyo, JPN, 105-0012

Website

https://www.noile-immune.com

Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.

Noile-Immune Biotech Headlines

No Headlines